Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients

Annals of Hematology

Volumn 79, Issue 3, 2000, Pages 152-157

  Vandercam, B ^a   Gerain J ^a   Humblet, Y ^a   Ferrant, A ^a   Wauters, G ^a   Moreau, M ^a   Longueville, J ^a   Symann, M ^a   Straetmans, N ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Ceftazidime; Glycopeptide; Immunocompromised host; Infections; Meropenem; Neutropenia

Indexed keywords

CEFTAZIDIME; GLYCOPEPTIDE; MEROPENEM; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0344002724     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050571     Document Type: Article

References (21)

1. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332
2. Hughes WT, Armstrong D, Bodey GP. et al. (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551-573
3. De Pauw B, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 120:834-844
4. Nováková I, Donnelly JP, De Pauw B (1990) Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteraemia. Scand J Infect Dis 22:705-711
5. Pizzo PA, Hathborn JW, Hiemenz J, et al. (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558
6. Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 164:907-916
7. Cometta A, Calandra T, Gaya H, et al. (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108-1115
8. EORTC International Antimicrobial Therapy Co-operative Group and the National Cancer Institute of Canada-Clinical Trials Group (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958
9. EORTC International Antimicrobial Therapy Co-operative Group (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39:445-452
10. The International Antimicrobial Therapy Co-operative Group of the EORTC (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593
11. Freifeld AG, Walsh T, Marshall D, et al. (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
12. Rolston KVI, Berkey P, Bodey GP, et al. (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
13. Norrby SR, Vandercam B, Louie T, et al. (1987) Imipenem/ cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis Suppl 52:65-78
14. Winston DJ, Ho WG, Bruckner DA, Champlin RE (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 115:849-859
15. Klugman KP, Dagan R, The Meropenem Meningitis Study Group (1995) Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 39:1140-1146
16. Norrby SR, Newell PA, Faulkner KL, Lesky W (1995) Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 36[suppl A]:207-223
17. Schmutzhard E, Williams KJ, Vukmirovits V, et al. (1995) A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 36[suppl A]:85-97
18. Meropenem Study Group of Leuven, London and Nijmegen (1995) Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 36:185-200
19. Immunocompromised Host Society (1990) The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397-401
20. Hospital Infection Control Practices Advisory Committee (HICAC) (1995) Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16:105-113
21. Morris JG, Jr, Shay DK, Hebden JN, et al. (1995) Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 123:250-259